Wave Life Sciences' (WVE) PRISM technology platform is expected to support a robust pipeline for 2026 and its outlook, Wedbush said in a note Friday, adding the stock to its "Best Ideas List."

The upcoming WVE-007 higher-dose readouts in Q1 and Q2 2026, a WVE-006 update in alpha-1 antitrypsin deficiency in Q1 2026, and an expected New Drug Application submission for WVE-N531 in Duchenne muscular dystrophy, are expected to support the company's numbers going forward, the investment firm said.

Wedbush said it raised its probability-of-success estimate for WVE-007 to 50% from 25% and models it as a potential monotherapy in obesity in addition to an add-on approach with GLP-1 therapies.

Wedbush's 2035 worldwide revenue view for WVE-007 is $8.3 billion across monotherapy and add-on use, up from a prior $2.5 billion estimate focused on add-on use alone, according to the note.

WVE-006 is also part of the company's broader validation case for Wave's RNA editing approach, including a possible 2026 clinical trial application submission for WVE-008 targeting PNPLA3 I148M liver disease, Wedbush analysts noted.

Wedbush maintained an outperform rating for the company and raised its price target to $33 from $20.

Price: 16.88, Change: +0.13, Percent Change: +0.78